Advancing the repurposing of ivermectin for malaria

Affiliations

¹ ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Instituto de Salud Tropical, Universidad de Navarra, Pamplona, Spain; Ifakara Health Institute, Ifakara, Tanzania.
² ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: rrabinov@hsph.harvard.edu.

Free article

Comment

Carlos Chaccour et al. Lancet. 2019.

Free article

. 2019 Apr 13;393(10180):1480-1481.

doi: 10.1016/S0140-6736(18)32613-8. Epub 2019 Mar 14.

¹ ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Instituto de Salud Tropical, Universidad de Navarra, Pamplona, Spain; Ifakara Health Institute, Ifakara, Tanzania.
² ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: rrabinov@hsph.harvard.edu.

No abstract available

Comment on

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Foy BD, et al. Lancet. 2019 Apr 13;393(10180):1517-1526. doi: 10.1016/S0140-6736(18)32321-3. Epub 2019 Mar 14. Lancet. 2019. PMID: 30878222 Free PMC article. Clinical Trial.